{
    "clinical_study": {
        "@rank": "131158", 
        "acronym": "POM MM 014", 
        "arm_group": {
            "arm_group_label": "Pomalidomide + dexamethasone", 
            "arm_group_type": "Experimental", 
            "description": "Each subject enrolled in the study will take oral pomalidomide (4 mg) once daily on Days 1-21 and dexamethasone 40 mg/day (< 75 years old) or 20 mg/day (>75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle."
        }, 
        "brief_summary": {
            "textblock": "This trial will evaluate the efficacy and safety of combination 3rd line treatment of\n      Pomalidomide (POM) and  low-doseDexamethasone (LD-Dex) in subjects with relapsed or\n      refractory multiple myeloma who have received a second line treatment of lenalidomide plus\n      dexamethasone.\n\n      This trial will test the hypothesis that the proportion  of patients will have an Overall\n      Response Rate (ORR) of > 30 %  to reveal that Pomalidomide is efficacious in pre-treated\n      patients who are refractory to lenalidomide."
        }, 
        "brief_title": "Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma Following Lenalidomide Plus Low Dose Dexamethasone as Second Line Treatment.", 
        "completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multi-center, single-arm, open-label, phase 2 trial designed to further evaluate\n      the efficacy and safety of combination Pomalidomide and Low Dose-Dexamethasone in subjects\n      with relapsed  or refractory multiple myeloma who have become refractory to a second line\n      treatment of lenalidomide.\n\n      This trial will assess, Overall Response Rate (ORR), Overall Survival (OS), Progression-Free\n      Survival (PFS), Duration of Response (DoR), Time to Response (TTR), Time to Progression(TTP)\n      and safety."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Adults ( age \u2265 18 years at the time of signing the informed consent document) with\n             documented diagnosis of multiple myeloma and measurable disease (serum M-protein \u2265\n             0.5 dL or urine M-protein \u2265 200 mg/24 hours).\n\n             2. Subjects must have received 2 prior treatment lines of anti-myeloma therapy. 3.\n             All subjects must have received prior treatment with LEN or a LEN-containing regimen\n             for at least 2 consecutive cycles as the second-line treatment regimen.\n\n             4. All subjects must have documented disease progression during or after their last\n             anti-myeloma therapy.\n\n             5. Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status\n             score of 0, 1, or 2.\n\n             6. Subjects must understand and voluntarily sign an informed consent prior to any\n             study related assessments/procedures being conducted.\n\n             7. Subjects must be able to adhere to the study visit schedule and other protocol\n             requirements.\n\n             8. All subjects must provide an adequate bone marrow sample at screening that\n             definitively evaluates the presence or absence of myelodysplastic changes.\n\n             9. Females with child-bearing  potential (FCBP\u2020 ) must agree to use 2 reliable forms\n             of contraception simultaneously or practice complete abstinence from heterosexual\n             contact for at least 28 days before starting study drug, while participating in the\n             study (including during dose interruptions), and for at least 28 days after study\n             treatment discontinuation and must agree to regular pregnancy testing during this\n             timeframe.\n\n             10. Females must agree to abstain from breastfeeding during study participation and\n             28 days after study drug discontinuation.\n\n             11. Males must agree to use a latex condom during any sexual contact with female of\n             childbearing potential (FCBP) while participating in the study and for 28 days\n             following discontinuation from this study, even if he has undergone a successful\n             vasectomy.\n\n             12. Males must also agree to refrain from donating semen or sperm during the\n             treatment phase and for 28 days after discontinuation from this study treatment.\n\n             13. All subjects must agree to refrain from donating blood while on study therapy and\n             for 28 days after discontinuation from this study treatment.\n\n             14. All subjects must agree not to share medication.\n\n        Exclusion Criteria:\n\n          -  1. Any of the following laboratory abnormalities:\n\n               -  Absolute neutrophil count < 1,000/\u03bcL\n\n               -  Platelet count < 75,000/\u00b5L for subjects in whom < 50% of bone marrow nucleated\n                  cells are plasma cells; or a platelet count < 30,000/\u00b5L for subjects in whom \u2265\n                  50% of bone marrow nucleated cells are plasma cells.\n\n               -  Severe renal impairment (Creatinine Clearance < 30 mL/min) requiring dialysis.\n\n               -  Corrected serum calcium > 11.5 mdL (> 2.8 mmol/L)\n\n               -  Hemoglobin < 8 dL (< 4.9 mmol/L; prior red blood cell transfusion or recombinant\n                  human erythropoietin use is permitted)\n\n               -  Serum  glutamic-oxaloacetic transaminase(SGOT)/ aspartate aminotransferase or\n                  glutamic-pyruvic transaminase (SGPT)/alanine aminotransferase (ALT) > 3.0 x ULN\n\n               -  Serum total bilirubin > 2.0 mdL (34.2 \u03bcmol/L); or > 3.0 x ULN for subjects with\n                  hereditary benign hyperbilirubinemia 2. Prior history of malignancies, other\n                  than multiple myeloma, unless the subject has been free of the disease for \u2265 5\n                  years.  Allowed exceptions include the following:\n\n               -  Basal or squamous cell carcinoma of the skin\n\n               -  Carcinoma in situ of the cervix or breast\n\n               -  Incidental histological finding of prostate cancer (TNM [tumor, nodes,\n                  metastasis]  stage of T1a or T1b) 3. Previous therapy with Pomalidomide 4.\n                  Hypersensitivity to thalidomide, lenalidomide, or dexamethasone (this includes \u2265\n                  Grade 3 rash during prior thalidomide or lenalidomide therapy) 5. Subjects who\n                  received an allogeneic bone marrow or allogeneic peripheral blood stem cell\n                  transplant less than 12 months prior to initiation of study treatment and who\n                  have not discontinued immunosuppressive treatment for at least 4 weeks prior to\n                  initiation of study treatment and are currently dependent on such treatment.\n\n                  6. Subjects with any one of the following:\n\n               -  Congestive heart failure (New York Heart Association Class III or IV)\n\n               -  Myocardial infarction within 12 months prior to starting study treatment\n\n               -  Unstable or poorly controlled angina pectoris, including Prinzmetal's variant\n                  angina pectoris 7. Subjects who received any of the following within 14 days of\n                  initiation of study treatment:\n\n               -  Major surgery (kyphoplasty is not considered major surgery)\n\n               -  Use of any anti-myeloma drug therapy 8. Use of any investigational agents within\n                  28 days or 5 half-lives (whichever is longer) of treatment, unless approved by\n                  the sponsor.\n\n                  9. Incidence of gastrointestinal disease that may significantly alter the\n                  absorption of Pomalidomide.\n\n                  10. Subjects unable or unwilling to undergo antithrombotic prophylactic\n                  treatment 11. Any serious medical condition, laboratory abnormality, or\n                  psychiatric illness that would prevent the subject from signing the informed\n                  consent document.\n\n                  12. Pregnant or breastfeeding females 13. Known Human immunodeficiency virus\n                  positivity; active infectious hepatitis A, B, or C; or chronic hepatitis B or C"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "85", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01946477", 
            "org_study_id": "CC-4047-MM-014"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pomalidomide + dexamethasone", 
                "intervention_name": "Pomalidomide", 
                "intervention_type": "Drug", 
                "other_name": "CC-4047"
            }, 
            {
                "arm_group_label": "Pomalidomide + dexamethasone", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug", 
                "other_name": "dex"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "Lenalidomide", 
                "Thalidomide", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Multiple Myeloma, MM, cancer, oncology, hematology, plasma, neoplasm, plasmacytoma", 
        "lastchanged_date": "May 1, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Pleasant Hill", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94523"
                    }, 
                    "name": "Bay Area Cancer Research Group, LLC"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Whittier", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90603"
                    }, 
                    "name": "Innovative Clinical Research Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Westminster", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21157"
                    }, 
                    "name": "Carroll Regional Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64111"
                    }, 
                    "name": "St. Luke's Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "Hackensack University Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hershey", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "17033"
                    }, 
                    "name": "Penn State Hershey Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spokane", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "99218"
                    }, 
                    "name": "Cancer Care Northwest"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Multicenter, Single-Arm, Open-Label Study of Pomalidomide in Combination With Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-Based Therapy in the Second-Line Setting", 
        "overall_contact": {
            "email": "clinicaltrialdisclosure@celgene.com", 
            "last_name": "Associate Director Clinical Trial Disclosure", 
            "phone": "1-888-260-1599"
        }, 
        "overall_official": {
            "affiliation": "Celgene Corporation", 
            "last_name": "Yasir Nagarwala, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint will be the Overall Response Rate (ORR) by modified International Myeloma Working Group (mIMWG) criteria and will be based on the best response prior to the time frame. ORR will consist of the responses of PR or better (Complete Response -CR, Very Good Partial Response-VGPR or Partial Response- PR).", 
            "measure": "Overall response rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "Approximately 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01946477"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall survival will be calculated as the time from start of treatment until the time of death from any cause. If no death is recorded the subject will be censored at the time the subject was last known to be alive.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 years"
            }, 
            {
                "description": "Progression-free survival will be calculated as the time from start of treatment until the time of PD (as determined by the site Investigator based on the mIMWG criteria) or death from any cause on study treatment, whichever comes first. Subjects not experiencing a documented progression will be censored at the time of their last response assessment (or at the time of trial enrollment if no assessment was conducted).", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 years"
            }, 
            {
                "description": "Duration of response, calculated for responders only, is defined as time from the initial documented response (PR or better) to the first confirmed PD or until death from any cause. Subjects without a documented progression will be censored at the time of their last response assessment", 
                "measure": "Duration of Response (DoR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 years"
            }, 
            {
                "description": "Time to response, calculated for responders only, is calculated as the time from the start of treatment to the first documented response (PR or better) based on modified International Working Group ( mIMWG) criteria.", 
                "measure": "Time to Response (TTR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Time to progression will be calculated as the time from start of treatment until PD (as determined by the site Investigator based on the mIMWG criteria) or death from progressive disease. Subjects not experiencing a documented progression will be censored at the time of their last response assessment (or at the time of trial enrollment if no assessment was conducted).", 
                "measure": "Time to progression (TTP)", 
                "safety_issue": "No", 
                "time_frame": "6 months after 100% enrollment and 5 years from Last Patient First Visit"
            }, 
            {
                "description": "Number of participants with adverse events including secondary primary malignancies.", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 7 years"
            }
        ], 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}